Artiva Biotherapeutics, Inc.

The momentum for this stock is not very good. Artiva Biotherapeutics, Inc. is not a good value stock. Artiva Biotherapeutics, Inc. is not a good growth stock. Artiva Biotherapeutics, Inc. is not very popular among insiders. Tradey thinks it is not wise to invest in Artiva Biotherapeutics, Inc..
Log in to see more information.
ARTV Fundamental Data by TradingView

News

Artiva Biotherapeutics to Participate in the 2024 Cantor Fitzgerald Global Healthcare Conference
Artiva Biotherapeutics to Participate in the 2024 Cantor Fitzgerald Global Healthcare Conference

Globe Newswire SAN DIEGO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell...\n more…

Wedbush Reiterates Outperform Rating for Artiva Biotherapeutics (NASDAQ:ARTV)
Wedbush Reiterates Outperform Rating for Artiva Biotherapeutics (NASDAQ:ARTV)

Ticker Report Artiva Biotherapeutics (NASDAQ:ARTV - Get Free Report)s stock had its "outperform" rating reiterated by Wedbush in a research note issued on Friday, RTT News reports. They presently have a...\n more…

Artiva Biotherapeutics (NASDAQ:ARTV) Given "Outperform" Rating at Wedbush
Artiva Biotherapeutics (NASDAQ:ARTV) Given "Outperform" Rating at Wedbush

Zolmax Artiva Biotherapeutics (NASDAQ:ARTV - Get Free Report)s stock had its "outperform" rating restated by stock analysts at Wedbush in a research report issued to clients and investors on Friday...\n more…

Buy Rating Affirmed for Artiva Biotherapeutics Amidst Clinical Advancements and Strong Financials
Buy Rating Affirmed for Artiva Biotherapeutics Amidst Clinical Advancements and Strong Financials

TipRanks Financial Blog Analyst Gil Blum from Needham maintained a Buy rating on Artiva Biotherapeutics, Inc. (ARTV - Research Report) and keeping the price target at $23....\n more…

Artiva Biotherapeutics reports Q2 EPS ($22.00) vs. ($14.09) last year
Artiva Biotherapeutics reports Q2 EPS ($22.00) vs. ($14.09) last year

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Artiva Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
Artiva Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Globe Newswire Strong balance sheet with successful completion of upsized $179.0 million initial public offering Treatment initiated in the first patient in an investigator-initiated basket trial of AlloNK...\n more…